Study on the relationship between constipation, colonic mucosal inflammation, intestinal LPS and Parkinson's disease

Abstract

Abstract:

AIM: To investigate the correlationship between intestinal symptoms (constipation), colon pathological changes, lipopolysaccharide（LPS）and Parkinson's disease（PD） so as to provide theoretical and experimental basis for the early detection of PD and its pathogenesis. METHODS: 102 PD patients were randomly divided into three groups through constipation questionnaire and discriminant analysis. Multivariate logistic regression analysis was used to analyze the relationship between the types of constipation and age, course of disease as well as course of constipation. 6 PD patients with constipation in were performed colonoscopy, and the infiltration of lymphocytes in colonic mucosa was detected by immunohistochemistry. LPS of 78 PD patients (23 cases without constipation and 55 cases with constipation) were detected by dynamic turbidimetric limulus test. RESULTS: (1) Within the total 102 PD patients, 23 cases presented without constipation while 79 cases with constipation, among which the STC, Mixed, RED were 31 cases (39.24%), 33 cases (41.77%) and 15 cases (18.99%) , respectively. (2) The colon mucosa of 6 PD patients with constipation showed chronic inflammation and a large number of CD+4 cell infiltration.(3) There were 15 cases of PD patients with the amount of LPS more than 0.1 EU/mL, 29 cases 0.1 to 0.01 EU/mL, and 34 cases <0.01 EU/mL among the 78 cases of PD patients, and the increased LPS was related to the constipation of PD patients. CONCLUSION: Constipation, colonic mucosal inflammation, chronic low-grade inflammation-induced intestinal LPS are associated with the occurrence and development of PD.

Key words: Parkinson's disease, constipation, lipopolysaccharide

CLC Number:

R742
R574

LIU Xiaolin, YU Meiling, XIE Jing, ZHANG Lina, XU Wenfang, YE Ming, LI Qianqian, CHEN Yuhua. Study on the relationship between constipation, colonic mucosal inflammation, intestinal LPS and Parkinson's disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 456-460.

References

［1］Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease［J］. Mov Disord, 2012 , 27(6): 709-715.
［2］Chen Y, Yu M, LIU X, et al. Clinical characteristics and peripheral T cell subsets in Parkinson's disease patients with constipation［J］. Int J Clin Exp Pathol, 2015;8(3):2495-2504.
［3］Hamza TH, Zabetian CP, Tenesa A,et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease［J］. Nat Genet, 2010; 42: 781-785.
［4］Knowles CH, Eccersley AJ, Scott SM, et al. Linear discriminant analysis of symptoms in patients with chronic constipation: validation of a new scoring system (KESS) ［J］. Dis Colon Rectum, 2000, 43: 1419-1426.
［5］McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and braak hypothesis［J］. Mov Disord, 2015,4(5)321-325.
［6］Bogunovic M. ILC3s and the willow tree of voices［J］, Immunity , 2016, 45,238- 239.
［7］Abdul-Aziz MA, Cooper A, Weyrich LS. Exploring relationships between host genome and microbiome: new insights from genome-wide association studies［J］.Front Microbiol, 2016,7:1611.
［8］Goodrich JK, Davenport ER, Waters JL,et al. Cross-species comparisons of host genetic associations with the microbiome［J］. Science, 2016,352(6285):532-535.
［9］Arnolds KL, Lozupone CA. Striking a balance with help from our little friends-how the gut microbiota contributes to immune homeostasis［J］. Yale Biol Med, 2016 , 89(3):389-395.
［10］Hand TW, Vujkovic-Cvijin I, Ridaura VK, et al. Linking the microbiota, chronic disease, and the immune system［J］. Trends Endocrinol Metab, 2016,27(12):831-843.
［11］Eisenstein M. Microbiome: bacterial broadband［J］. Nature, 2016, 533(7603):S104-106.
［12］Gury-BenAri M, Thaiss CA, Serafini N, et al.The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome［J］. Cell, 2016, 166(5):1231-1246.
［13］Matcovitch-Natan O, Winter DR, Giladi A, et al. Microglia development follows a stepwise program to regulate brain homeostasis［J］. Science, 2016,353(6301) 1251-1254.
［14］Nemoto H, Friedland RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration［J］. J Alzheimers Dis, 2015, 45(2)349-362.
［15］Scheperjans FL, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype［J］. Mov Disord, 2015, 30(3):350-358.
［16］Unger MM,Spiegel J,Dillmann KU,et al.Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls［J］.Parkinsonism Relat Disord,2016,32:66-72.
［17］Zhang J, Stanton DM, Nguyen XV, et al. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits［J］. Neurosci, 2005, 135(3): 829-838.
［18］Choi DY, Zhang J, Bing G. Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats［J］. NeurobiolAging, 2010, 31(9): 1649-1653.
［19］Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration［J］. Glia, 2007, 55(5): 453-462.
［20］Pal GD, Shaikh M, Forsyth CB, et al. Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson's disease［J］. Frontiers Neurosci, 2015, 9: 306.

[1]	ZHANG Lei, XIAO Xingpeng, DING Huang . Silencing ZKSCAN3 gene expression aggravates lung injury induced by LPS in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 164-170.
[2]	FU Xiaomei, HUO Ran, DENG Sai, LIN Chaojin, FAN Jinghao, WANG Ping, LI Songpei, QIN Aiping, ZOU Minghui, YU Xiyong. Exosomes derived from LPS-stimulated bone marrow mesenchymal stem cell improve myocardial inflammation and fibrosis after myocardial infarction in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 841-851.
[3]	LIU Huanmiao, CHEN Zhuohui, WU Di, HUANG Xueting, WAN Qiquan. Insulin attenuates the inhibition effect of lipopolysaccharide on Na+-K+-ATPase α1 via PI3K/AKT and PI3K/ERK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 896-902.
[4]	CHEN Shaozhong, LIN Meise, CHENG Limin, ZHU Lele. Effects of salidroside injection on pulmonary vascular permeability in rats with septic shock induced lung injury induced by lipopolysaccharide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1256-1262.
[5]	CAO Yingya, CHEN Qun, WANG Zhen, WU Jingyi, JIANG Xiaogan, JIN Xiaoju, LU Weihua. Role of macrophages in LPS-induced apoptosis of intestinal epithelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1142-1146.
[6]	ZHENG Shuang, FU Qinlei, ZHOU Lingping, PENG Chuanpeng, XU Honglei. Study on interleukin-17A during early inflammatory response in mice with LPS-induced acute lung injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 148-153.
[7]	ZHONG Zhengling，ZHANG Fei，JIANG Yuhua，ZHANG Weiting，TONG Jiucui，LI Juan，CHU Jiru，XIE Haitang. Protective effects of Ferulic acid on acute liver injury induced by D-GalN/LPS in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1335-1339.
[8]	WANG Di, ZHANG Huanhuan, FANG Jie, ZHONG Yushen, YU Chenhuan. Effects of limoninon on LPS-induced acute lung injury in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 8-12.
[9]	ZHAO Tianwen, TANG Hanxiao, HUANG Wenjing, BAO Yishu, CHEN Congcong, CHEN Dongsheng, SHENG Yunjie, ZHANG Yongsheng. Effects of Jiawei Zengye decoction on diphenoxylate-induced constipation in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 866-869.
[10]	GE Bobo，QU Hongdang，CHEN Yuhua，HU Caicai，LI Li，JIANG Mujun，XU Juanjuan. LPS-induced chronic Parkinson's disease in mice α-synuclein in the emergence and metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 241-248.
[11]	CHEN Yan, YE Bin, MOU Wen-yuan, YU Cheng-bo, LIN Bu, YIN Xiang-peng, XU Hong-miao. Effect of anti-tumor necrosis factor antibody on TRAIL and TNF-α expression induced by lipopolysaccharide in human periodontal ligament fibroblasts [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 493-498.
[12]	ZHONG Cheng-liang, HU Si-yuan. Key technologies elements of clinical study of TCM new drugs on children's functional constipation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1025-1030.
[13]	MO Hong-ying, JIANG Yong-nan, LI Yi-min, LAI Le, XIAO Zheng-lun. Effect of MIF siRNA on the expression of Toll-like receptors and down stream signaling components in A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 382-387.
[14]	CHEN Jie, LI Rui-ming, XU Jing, GUAN Bi-qiong, LUO Zi-ling. Effect of Wedelolactone on COX-2, NO and TNF-α expression in lipopolysaccharide induced RAW264.7 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 171-174.
[15]	ZHU Hai-long, ZHANG Gen-bao, LI Wei, ZHANG Cui. Protective effects of ERK1/2 inhibitor PD98059 on multiple organ dysfunction in disseminated- intravascular-coagulation rat [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 159-163.